What is it about?

We review current literature, highlighting PPARs’ key role in asthma pathogenesis and their agonists’ therapeutic potential.

Featured Image

Why is it important?

sthma affects approximately 300 million people worldwide, significantly impacting quality of life and healthcare costs. While current therapies are effective in controlling many patients’ symptoms, a large number continue to experience exacerbations or treatment-related adverse effects. Alternative therapies are thus urgently needed. Accumulating evidence has shown that the peroxisome proliferator-activated receptor (PPAR) family of nuclear hormone receptors, comprising PPARα, PPARβ/δ, and PPARγ, is involved in asthma pathogenesis and that ligand-induced activation of these receptors suppresses asthma pathology. PPAR agonists exert their anti-inflammatory effects primarily by suppressing pro-inflammatory mediators and antagonizing the pro-inflammatory functions of various cell types relevant to asthma pathophysiology. Experimental findings strongly support the potential clinical benefits of PPAR agonists in the treatment of asthma.


With additional research and rigorous clinical studies, PPARs may become attractive therapeutic targets in this disease.

Aravind Reddy Tarugu
University of Pittsburgh

Read the Original

This page is a summary of: PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma, Nuclear Receptor Research, January 2018, KenzPub,
DOI: 10.11131/2018/101306.
You can read the full text:




The following have contributed to this page